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Introduction
Estrogen  mimics  (xenoestrogens)  are  a  group  of 
  environmental  contaminants  which  cause  reproductive 
  dysfunctions in wildlife and interfere with cancer diseases 
in humans. Natural or synthetic estrogenic compounds can 
induce cell proliferation, hypertrophy of female secondary 
sex organs and the synthesis of cell type-specific proteins 
(Hertz  1985).  Dietary  estrogens  are  either  produced  by 
plants (phytoestrogens) or by fungi (myco-estrogens) that 
infect plants or their products (Kurzer and Xu 1997).
The  human  diet  contains  several  non-estroidal  estro-
genic compounds, which are structurally similar to natural 
or synthetic estrogens or anti-estrogens. Zearalenone (Zen) 
is a myco-estrogen with non-estrogenic chemical structure 
(resorcylic acid lactones) which is produced by several spe-
cies of Fusarium fungi and widely contaminates agricultural 
products  (Bennet  and  Shotwel  1979;  Sutton  et  al.  1980; 
Trenholm et al. 1985). Zen exists in almost every agricultural 
product including cereals, mixed feeds, and rice, but corn is 
the most frequently contaminated commodity (Tanak et al. 
1988; Gareis et al. 1989; Veldman et al. 1992). After con-
sumption, Zen can be metabolized in the body by reduction 
of the keto-group at C-6’ and convertion to two major stereo 
isomers  metabolites,  -  and  -Zearalenol  (-  and  -Zel) 
(Kiessling and Pattersson 1978; Mirocha et al. 1981; Kuiper-
Goodman et al. 1987). The more potent estrogenic active 
metabolite of Zen is -Zel, which is also naturally produced 
by fungi (Richardson et al. 1985; Erasmuson et al. 1994).
The  effect  of  these  myco-estrogens  in  animals  is 
Estrogenic Syndrome with clinical hyperestrogenism mani-
festations  in  those  fed  contaminated  grains,  and  causes 
infertility as a major problem in animal husbandry, espe-
cially  in  swine  (Chang  et  al.  1979;  Etienne  and  Jemmali 
1982). Also, some derivatives of zearalenone like Zeranol 
(Ralgro), a synthetic product, have androgenic activity and 
are used as growth promotors in animals (Baldwin et al. 
1983) and humans, because of the estrogenic properties, 
can interact to hormone receptors and play an important 
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abstract
Zearalenone (Zen) is a mycotoxin with estrogenic effect which contaminates cereals. In cell culture, Zen and 
its metabolite, α-Zearalenol (α-Zel), stimulate breast cancer cells growth. Today hormone-dependent cancers 
are important because of high incidence and death rate. Previous studies showed that Zen and α-Zel have an 
effect on hormone-dependent cancers. This study explains the effects of the mentioned compounds in compari-
son with Raloxifene as an anti-estrogen. Cell culture technique was used with MDA-MB-231 and T47D cells for 
evaluation of compounds. MDA-MB-231 cells were used as negative control and also for proving that treatment 
compounds merely affect, due to their proliferation activity in the applied doses. According to the Resazurine-
based method, for toxicity assay, none of the test compounds have an effect on MDA-MB-231 cells but do effect 
the growth of T47D cells. Zen and α-Zel at low concentrations (10−8–10−9 M) stimulated T47D cell growth and 
Raloxifene strongly inhibited cell growth induced by Zen and α-Zel. There is a noticeable result in controlling 
diet of hormonal carcinogenic compounds and applying novel anti-estrogens for prevention and treatment of 
hormone-dependent cancers.
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role in   hormone-dependent diseases like breast (Martin et 
al. 1978; Makela and Davis 1994; Dees et al. 1997; Zava et al. 
1997) and endometrium cancer (Tomaszewski et al. 1998; 
Withanage et al. 2001).
Recently,  environmental  scientists  have  paid  attention 
to  the  relationship  between  dietary  estrogens  and  hor-
mone-dependent cancer (Barnes 1998; Clarke et al. 2001), 
especially breast cancer, which is the most common cause 
of death in women worldwide (Key et al. 2001; Lacey et al. 
2002). Although their relative contribution to the genesis of 
breast cancer in humans appears to be controversial (Safe 
1997), xenoestrogenic compounds can add to the estrogenic 
burden and therefore could be a potential source of estro-
genic  exposure  in  women,  especially  in  prepubertal  and 
postmenopausal years. Some studies have shown that Zen 
stimulates the growth of MCF-7 breast cancer cell lines in 
vitro (Makela and Davis 1994; Zava et al. 1997), and enlarge 
mammary tumors in mice (Schoental 1974), reflecting its 
estrogen receptor-agonist properties.
In  present  study,  we  examined  the  effect  of  Zen  and 
-Zel  at  different  concentrations  on  T47D,  estrogen 
  receptor-positive,  and  MDA-MB-231,  estrogen  receptor-
negative breast cancer cell lines as negative control cells, 
for in vitro model determination of these myco-estrogens 
and 17--Estradiol (E2) as positive control agent. We also 
investigated the preventive effect of Raloxifene, new SERMs 
(Selective  Estrogen  Receptor  Modulators)  with  mixed 
agonist/antagonist  properties,  on  estrogen  receptor,  and 
identified the potential reduction in the risk of breast can-
cer (Barrett-connor 2001; Kim et al. 2002). The effects of 
Raloxifene on the above mentioned cell lines alone and in 
combination with test myco-estrogens and E2 have been 
studied to show the anti-estrogenic effect on T47D cells.
Materials and methods
Chemicals
Zearalenone, -Zearalenol, 17--Estradiol, and Raloxifene 
were purchased from Sigma (Steinem, Germany). The stock 
solutions of estrogenic compounds were prepared in absolute 
ethanol. The final concentration of solvent was 0.5% (v/v). 
The stock solutions were stored at 2–8°C. Serial dilutions for 
all compounds were made in culture medium. RPMI 1640, 
Dulbecco’s Modified Eagle Medium or DMEM, and their 
phenolred-free,  Fetal  Bovine  Serum  (FBS),  L-Glutamine, 
Trypsin-EDTA, and Penicillin-Streptomycin were purchased 
from Gibco BRL (Grand Island, NY), and Charcoal-Dextran 
Treated FBS purchases from Hyclone (Logan, Utah).
Cell lines and culture
Breast  cancer  human  cell  lines,  T47D,  passage  number 
18–25 (estrogen receptor-positive, ER+), and MDA-MB-231, 
passage  number  44-51  (estrogen  receptor-negative,  ER−) 
were  obtained  from  American  Type  Culture  Collection 
(Manassas, Virginia). T47D cells were maintained in RPMI 
1640 with added 5% FBS, 1% L-Glutamine, and Penicillin-
Streptomycin, and then cells were incubated at 37°C in a 
5% concentration of CO2. MDA-MB-231 were maintained in 
DMEM with added 10% FBS, 1% L-Glutamine, and Penicillin-
Streptomycin at 37°C in a 5% concentration of CO2. Two days 
before experiment, the media of cells were removed and 
phenol  red-free  medium  with  Charcoal  Dextran  Treated 
FBS was added to cells.
Experiments
Cells  were  harvested  by  Trypsin-EDTA  and  resuspended 
in  fresh  medium  and  seeded  in  96-well  culture  plates  at 
4000 cells/well. After 1 day incubation in order to cells attach-
ing, different concentrations of test compounds were pre-
pared by serial dilution (1:10) and each concentration added 
to wells as quadrupled from 10−4 M to 10−14 M. In each plate, 
there were control wells (cells without test compounds) and 
blank wells (the medium only). On day 3 the medium was 
removed and fresh medium with these compounds were 
added to cells. All compounds were added to cells alone to 
observe the effects and then Zen, -Zel, E2 in combination 
with Raloxifene, added to the cells. After 7 days the plates 
were prepared for viability assay.
Viability Assay
In order to determinate cell viability, the Resazurine-based 
method  was  used.  Briefiy,  the  method  is  designated  for 
spectrophotometrically or fluorometrically determining cell 
numbers as a function of metabolic activity using the dye 
Resazurine. Bio-reduction of the dye by viable cells reduces 
the amount of its oxidized form (blue) and concomitantly 
increases the amount of its fluorescent intermediate (red), 
indicating the degree of viability caused by the test com-
pounds. After the exposure time of compounds, the media 
of plates were removed and 10% (v/v) Resazurine in phenol 
red-free medium with Charcoal Dextran treated with FBS was 
added to cells in plates and placed in the incubator. Between 
2–4 h of exposure to the dye, the plates were removed from 
the incubator and the viability was measured fluorometri-
cally  while  monitoring  the  increase  in  fluorescence  at  a 
wavelength 590 nm using an excitation wavelength of 560 nm 
by multi-plate reader. The plate reader was a dual-scanning 
spectrofluorometer,  SPECTR  Amax  GEMINI  XS  made  by 
Molecular Devices Co. (Sunnyvale, CA).
Statistical analysis
Data are presented as mean ± SD. Significance of results was 
assayed by using ANOVA, followed by Dennett’s Comparison 
of  Treatment  against  Control  with  p < 0.001  evaluated  as 
  statistically significant.
Result
MDA-MB-231 cells (estrogen receptor-negative breast can-
cer line) were used as negative control for testing the estro-
genic effect of tested compounds. As shown in Figure 1, none 
of the estrogenic test compounds had an effect on growth of 
this cell line in the used concentrations (10−6–10−12 M), nei-
ther stimulation nor suppression.248    Shahram Shoeibi et al.
Figure 2 shows the effect of different concentrations of 
Zen  on  T47D  cells.  At  low  concentrations,  below  10−9 M, 
there were no effects on growth of cells, at concentrations 
between  10−9  M  and  10−6 M,  the  stimulatory  effect  was 
observed and the most was at 10−8 M, about 2-fold stimula-
tion of the growth in comparison with control cells. At high 
concentrations,  above  10−6 M, the growth was suppressed 
and it seems that the toxic effect of Zen on cells appears in 
these concentrations.
In Figure 3 the effect of test compounds on T47D cells were 
shown. E2, a potent ligand for estrogenic receptors, at con-
centration of 10−8 M, has shown the most stimulatory effect on 
the growth of cells as about 2-fold in comparison with control 
cells. Also, Zen and -Zel have stimulated the growth of cells 
at low concentrations (Zen 10−8 M and -Zel 10−9 M), which 
was comparable with E2. Raloxifene, a novel SERMs, strongly 
inhibited the growth of cells at low concentration (10−10 M).
We also examined the simultaneous effect of equivalent 
concentration of stimulating test compounds (Zen, -Zel, 
and  E2)  against  Raloxifene,  which  is  shown  in  Figure  4. 
Raloxifene could suppress the stimulatory growth effect of 
Zen from 10−12 to 10−7 M concentrations in comparison with 
the results shown in Figure 2.
-Zel, which is more potent than Zen, could stimulate 
the proliferation of T47D cells from 10−9 to 10−6 M concen-
trations, although Raloxifene was inhibited from this effect 
moderately.
E2, as the most potent ligand for estrogen receptor, had 
a stronger effect on cell proliferation from 10−9 M concen-
tration and higher, the inhibitory effect of Raloxifene was 
weaker in comparison with other compounds.
Discussion
Hormone-dependent cancers are one of the most impor-
tant diseases because of their high incidence and death 
rate. Breast and endometrial cancers are examples of the 
mentioned diseases which mostly are estrogen-receptor 
dependent, thus chemicals with estrogenic properties may 
effect the promotion or prevention of this type of cancers.
Diet is one of the main factors in inducing, promoting, 
or preventing cancer. Foods include different components; 
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Figure  1.  Effects of Zen, -Zel, E2, and Raloxifene on growth of MDA-MB-231 cells. Cells were seeded in 96-wells (4 × 103/well) and after 7 days of 
exposure to different concentrations of test compounds, cell viability was determined by Resazurine-based method. Data are presented as mean ± SD 
(n = 4).
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Figure  2.  Effects of different concentration of Zen on growth of T47D cells. Cells were seeded in 96-wells (4 × 103/well) and after 7 days of exposure   
to different concentrations of test compounds, cell viability was determined by Resazurine-based method. Data are presented as mean ± SD (n = 4).Effects of zearalenone and a-Zearalenol  249
some of them, like vitamins, minerals, and fibers, are useful 
in prevention and treatment of cancers, and some are harm-
ful.  Natural  compounds  like  phyto-  and  myco-estrogens 
can interfere with hormonal receptors and affect hormone-
dependent cancers.
In this investigation we studied the response of affected 
cells by compounds with estrogenic properties. We used 
two types of breast cancer cell lines: MDA-MB-231 (ER−) 
as negative control and T47D (ER+) in order to observe 
that test compounds affect via interfering with estrogen 
receptors. In comparison between results shown in Figure 
1 and Figure 3, it is observed that test compounds interfere 
with receptors and resulted in this effect. Anyway the men-
tioned compounds may have other carcinogenic effects 
except proliferation of cells. The effect on MDA-MB-231 
impresses that, in applied doses of test compounds, they 
did  not  have  any  effect  on  cellular  level,  but  maybe  in 
higher doses, they could have a cytotoxic effect, which is 
shown in Figure 2, at higher than 10−5 M concentrations. 
It could be also considered that, according to the aim of 
study,  which  is  interaction  between  potent  estrogens 
against novel SERMs (Raloxifene), test compounds did not 
have any molecular effect, which concluded to prolifera-
tion respond.
Figure 3 shows that Zen and -Zel have strong effects 
on growth stimulation comparable with E2. The last results 
show that these mycotoxins can play an important role in 
promotion of estrogen-dependent cancer and cause pro-
liferation on related cells. Zen, after ingestion by humans 
or animals, can affect cells directly, or be metabolized by 
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Figure  4.  Effects of equivalent concentrations of Zen, -Zel, and E2 with Raloxifene on growth of T47D cells. Cells were seeded in 96-wells (4 × 103/well) 
and after 7 days of exposure to different concentrations of test compounds, cell viability was determined by Resazurine-based method. Data are presented 
as mean ± SD (n = 4).
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Figure  3.  Effects of Zen, -Zel, E2, and Raloxifene on growth of T47D cells. Cells were seeded in 96-wells (4 × 103/well) and after 7 days of exposure to 
different concentrations of test compounds, cell viability was determined by Resazurine-based method. Data are presented as mean ± SD (n = 4). ** 
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organs and converted to -Zel, which is more potent than 
the primary compound.
Raloxifene,  a  novel  SERM,  when  applied  against  Zen, 
-Zel,  and  E2  at  equivalent  concentrations,  inhibits  the 
increased proliferation stimulated by test compounds, which 
is shown in Figure 4. After further in vivo studies and clinical 
trials it could be considered as one of the helpful compound 
in prevention and treatment of hormone-dependent cancer 
against  biological  or  synthetic  chemical  with  estrogenic 
properties,  and  has  protective  effect  on  cells  containing 
estrogen receptors.
It is suggested to study other compounds with estro-
genic properties which have important roles in nutrition 
and environmental conditions of life. Also, because of the 
dose-dependent response of these compounds, some stud-
ies are focused on the dose–response effect and interaction 
with anti-estrogens together with anti-cancer agents like 
vitamins.
Raloxifene  alone  could  significantly  suppress  normal 
growth of T47D cells by about 40% (p < 0.01). This matter 
could be suggested for further studies. Raloxifene effectively 
inhibited cell proliferation induced by Zen, so whereas Zen 
is one of the hazards in human diet, anti-estrogens could 
be effective in peoples who consume agricultural products 
more in their diet, especially corn products.
-Zel  has  been  moderately  suppressed  by  Raloxifene, 
although  the  stimulatory  effect  of  it  was  observed.  -Zel 
does not directly exist in the diet, it is produced by metabo-
lization in the body and also could be a more hazardous 
compound.
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